Vera Therapeutics Inc (VERA)

NASD · Healthcare · Biotechnology · USA

Vera Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Vera Therapeutics is a late clinical-stage biotechnology company developing treatments for serious immunological diseases. Its lead product candidate, atacicept, is being evaluated for immunoglobulin A nephropathy and other autoimmune kidney diseases. The company also holds development rights to MAU868 for BK virus infections and to VT-109, a dual inhibitor in preclinical development.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Vera Therapeutics Inc stock.

Our verdict on VERA

Not valued: We cannot value this company yet.

We do not publish a value for this company: it has no growth history of its own to project.

ETFs with the most weight in VERA

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than VERA in Biotechnology

129 more in this industry show a wider margin of safety.

Is VERA undervalued or overvalued?

We do not publish a verdict on VERA yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of VERA?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history. We do not have it. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.